Dr Ilene Weitz reviews data on novel agents and their efficacy in enhancing quality of life and minimizing breakthrough events.

Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.